TERT and breast cancer: The observed alterations in BRCA1 and BRCA2 promoter activity are of a similar magnitude to that seen with other germline variants associated with BC risk (Michailidou et al., 2017), including a variant in the TERT promoter, which creates a new binding site for Ets factors and results in a 1.2–1.5‐fold increase in luciferase activity in a promoter reporter assay (Horn et al., 2013), and variants in the promoters of KLHDC7A and PIDD1 (Michailidou et al., 2017).